Sign In
Buy ALLO
$2.00
-0.0500 (-2.44%)
At Close: Jun 03, 2026
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
10:40am, Wednesday, 11'th Feb 2026
Here is how Allogene Therapeutics (ALLO) and McKesson (MCK) have performed compared to their sector so far this year.
Rapid Innovation is Reshaping Oncology: Stocks in Focus
09:01am, Thursday, 05'th Feb 2026
Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
08:30am, Thursday, 05'th Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of “Moderate Buy” by Brokerages
04:09am, Monday, 02'nd Feb 2026
Allogene Therapeutics, Inc. (NASDAQ: ALLO - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the company, Marketbeat.com repo
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
10:41am, Monday, 26'th Jan 2026
Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Head to Head Review: Allogene Therapeutics (NASDAQ:ALLO) and Imunon (NASDAQ:IMNN)
01:54am, Sunday, 11'th Jan 2026
Imunon (NASDAQ: IMNN - Get Free Report) and Allogene Therapeutics (NASDAQ: ALLO - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two bu
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
10:41am, Friday, 09'th Jan 2026
Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
08:30am, Thursday, 08'th Jan 2026
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
05:39pm, Monday, 15'th Dec 2025
Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
08:30am, Monday, 10'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T
06:08pm, Friday, 07'th Nov 2025
Allogene Therapeutics, Inc. is downgraded from Strong Buy to Hold due to setbacks in its pivotal phase 2 ALPHA3 trial. ALLO's cema-cel for Large B-Cell Lymphoma remains on track for a key futility ana
Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales
12:21pm, Friday, 07'th Nov 2025
ALLO's Q3 loss narrows to 19 cents per share, beating estimates, as R&D and G&A costs decline despite no product sales.
Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript
12:16am, Friday, 07'th Nov 2025
Allogene Therapeutics, Inc. ( ALLO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David C
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
04:05pm, Thursday, 06'th Nov 2025
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earli
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
09:04am, Monday, 03'rd Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA
